News | Heart Valve Technology | December 13, 2021

Foldax Gets Indian Approval to Start Clinical Trial of Tria Biopolymer Surgical Aortic Valve

The Tria biopolymer surgical aortic valve displayed at Beaumont Hospital, Royal Oak.

The Tria biopolymer surgical aortic valve displayed at Beaumont Hospital, Royal Oak.


December 13, 2021 - Foldax Inc. announced that the Drugs Controller General of India (DCGI), India’s regulatory body for medical devices, has approved initiation of a clinical trial of the Tria biopolymer surgical aortic heart valve. The Tria valve reimagines the heart valve by combining the company’s proprietary biopolymer – LifePolymer – with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants.

The trial will study the ability of the Tria biopolymer aortic valve to surgically treat patients with aortic valve disease and lead to commercial approval in India.

Today, 70 percent of aortic valve replacements being performed in India implant mechanical valves. Mechanical valves are durable but require life-long anticoagulant use to minimize blood clotting. Anticoagulant therapy creates an ongoing bleeding risk that can limit a patient’s lifestyle, diminish their quality of life, and potentially lead to hemorrhage and death.

“After promising outcomes from our U.S. early feasibility study, we are excited to expand our clinical study of the Tria biopolymer valve globally, beginning in India. This study is the first step to commercializing our device outside of the U.S.,” said Frank Maguire, chief executive officer of Foldax. “Our platform technology is well suited to one of the largest heart valve replacement markets in the world that has relied on mechanical heart valves to treat both aortic and mitral disease. The Tria valves are designed to be uniquely durable while sparing patients from the negative consequences of blood thinning medication. Additionally, our robotic manufacturing process allows us to consider in-country manufacturing with the same precision and quality as our U.S.-based manufacturing.”

Tria is the first and only heart valve to be robotically produced, which is possible due to its polymer leaflets that can be consistently manufactured with precise thicknesses and are designed to achieve a valve with predictable lifetime performance. 

The Tria heart valve is for investigational use only and is not available for commercial sale.

For more information: www.foldax.com


Related Content

News | Heart Valve Technology

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

Home November 22, 2022
Home
News | Heart Valve Technology

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

Home October 18, 2022
Home
News | Heart Valve Technology

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

Home October 18, 2022
Home
News | Heart Valve Technology

September 26, 2022 — Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates ...

Home September 26, 2022
Home
News | Heart Valve Technology

September 15, 2022 — Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with ...

Home September 15, 2022
Home
News | Heart Valve Technology

September 9, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers about potential clip ...

Home September 09, 2022
Home
News | Heart Valve Technology

May 19, 2022 — A study of 1-year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) ...

Home May 19, 2022
Home
News | Heart Valve Technology
May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of ...
Home May 05, 2022
Home
News | Heart Valve Technology

April 27, 2022 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall for the Medtronic Harmony ...

Home April 27, 2022
Home
News | Heart Valve Technology
March 2, 2022 – An international study led by a researcher from Tel Aviv University offers a novel technology that can ...
Home March 02, 2022
Home
Subscribe Now